Navigation Links
Antares Pharma Announces Positive Results from Application Site,Study for Anturol

ortly."

ANTUROL(R) ATD(TM) transdermal gel is intended to treat symptoms of overactive bladder (OAB), a lower urinary tract disorder resulting in a symptom syndrome including urgency with (OAB wet) or without (OAB dry) urge incontinence, usually with frequency and/or nocturia. OAB is estimated to affect more than more than 33 million people in the United States , and more than 22 million people in Europe. While OAB can affect a person at any age, it is most common among the elderly, with a prevalence of 33% to 61% in people over age 65. Despite its rising prevalence with age, OAB is treatable at every age. In recent published reports the market is described as one of the fastest-growing sectors in the pharmaceutical industry is and projected to exceed approximately $ 4 billion by 2010.

About Antares Pharma

Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares' current technology platforms include its ATD(TM) Advanced Transdermal Delivery system, and its related TecTix(TM) system for topical and transmucosal delivery, its Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/Vision(R) reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline, if approved, will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapoli
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/22/2014)... -- Influenza will affect as many as 200,000 people this ... States as high as 49,000 people.  The main ... person to person in respiratory droplets of coughs and sneezes. ... but kills much fewer people each year than the Flu. ... including sweat, saliva, blood and other bodily fluids. The Ebola ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
...  With increasing demands for time spreading consumers thin — ... to and from their many appointments — running errands ... simpler for shoppers always on the go, Shopko announces ... to quickly and easily refill and manage their pharmacy ...
... SAN FRANCISCO, Jan. 10, 2012  The University of California, San ... Sanofi (EURONEXT: SAN and NYSE: SNY ) to ... could lead to new therapies for both type 1 and ... will bring together scientists in three UCSF labs with deep ...
Cached Medicine Technology:Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 3UCSF, Sanofi Collaborate to Find New Diabetes Cures 4UCSF, Sanofi Collaborate to Find New Diabetes Cures 5
(Date:10/22/2014)... (PRWEB) October 22, 2014 Isabel ... of Allied Health Professions (ASAHP) Conference on October 22-24 ... CEO will participate in a panel discussion on Technology ... , Isabel Healthcare provides a diagnostic decision support tool ... the diagnosis skills of students and clinical learners. The ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... 7 The Generic Pharmaceutical Association (GPhA) will discuss the ... leading healthcare market intelligence company, revealing that generic pharmaceutical utilization ... care system in the last decade., What: ... $734, ...
... Edward Downs has been named chief executive officer of Renaissance Hospital ... ... Houston, TX (PRWEB) May 7, 2009 -- Renaissance Healthcare ... executive officer of Renaissance Hospital Dallas. The appointment was effective May ...
... and Payroll Solutions Leader Introduces Industry-Pioneering Application , ... ... HRO®, a leader in human resources and payroll solutions, announces ... is a bold fusion of the company’s legacy GenevaPlus and ...
... & Sportsclub Association (IHRSA) and fitness professionals across ... meet with their Congressional members, asking for their ... barriers from exercise, and to reward Americans for ... Annual IHRSA Summit for a Healthier America, fitness ...
... other common factors in home health care can make ... used discount medical supplies. TheMedicalSupplyDepot.com announces the new Auto ... care individuals, set up their orders ahead of time ... skin care, incontinence or wound care items they need ...
... Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 ... reported recent accomplishments and financial results for the quarter ... half of 2009 was to initiate and complete the ... in our cost cutting efforts and raised much needed ...
Cached Medicine News:Health News:Edward Downs Named CEO of Renaissance Hospital Dallas 2Health News:Unicorn HRO Unveils iCON 2Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 2Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 3Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 4Health News:Home Health Care Supplies 'Order Themselves' with New Auto Reorder from TheMedicalSupplyDepot.com 2Health News:Home Health Care Supplies 'Order Themselves' with New Auto Reorder from TheMedicalSupplyDepot.com 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Tips - 2l - 200l. Reduces DNA and ... packaged completely by automation. RNAse & DNAse free. ... and 10 racks/cs. AVR2 is the Cell Rack ... the Stacked Rack packaged 96 tips/rack and 10 ...
Medicine Products: